Gastroesophageal Junction Carcinoma — Trials

Gastroesophageal Junction Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 231
Recruiting: 126
Ph III recruiting: 18
Growth YoY: +44.2%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (86)

clinicaltrialsPublishedShowing 151–151 of 151 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00732745	Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction	terminated	Phase 1	9	Case Comprehensive Cancer CenterOTHER	1	Aug 22, 2011	clinicaltrials